Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia

Takahiro Maeda, Eiji Kikuchi, Masanori Hasegawa, Katsura Ishioka, Masayuki Hagiwara, Yasumasa Miyazaki, Toshiaki Shinojima, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective To evaluate the clinical response and adverse events (AEs) of solifenacin (SOL) or mirabegron (MIR) in benign prostatic hyperplasia patients with persistent overactive bladder (OAB) symptoms after dutasteride (DUT) treatment. Methods Fifty cases with residual OAB symptom score (OABSS) ≥5 and OABSS Q3 ≥2 after at least 6 months treatment of DUT were included in this study. Patients were administered 5 mg/d of SOL (N = 25) or 50 mg/d of MIR (N = 25), and International Prostate Symptom Score (IPSS) and OABSS were prospectively collected at 4 and 12 weeks. The safety was evaluated by changes in postvoided residual urine volume and the incidence of AEs. Results After DUT administration, the mean prostate volume, IPSS, and OABSS were 39.0 mL, 17.6, and 8.1, respectively. SOL 5 mg significantly reduced the IPSS, OABSS, and OABSS Q3 at 4 and at 12 weeks (-3.1, -2.7, -1.3; P <.05); however, 4 patients could not continue the SOL treatment owing to AEs. All patients could continue the 12 weeks of MIR treatment, and MIR 50 mg reduced IPSS and OABSS at 4 weeks and reduced IPSS, OABSS, and the OABSS Q3 (-3.0, -2.5, -0.9; P <.05) at 12 weeks. Postvoided residual urine volume increased by ≥100 mL after treatment in 2 cases in the SOL group but not in any patient in the MIR group. Conclusion Additional SOL or MIR might result in amelioration of the persistent OAB symptom after DUT treatment in patients with an enlarged prostate.

Original languageEnglish
Article number19056
Pages (from-to)1151-1155
Number of pages5
JournalUrology
Volume85
Issue number5
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Overactive Urinary Bladder
Prostatic Hyperplasia
Prostate
Residual Volume
Therapeutics
Urine
mirabegron
Dutasteride
Solifenacin Succinate
Safety
Incidence

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia. / Maeda, Takahiro; Kikuchi, Eiji; Hasegawa, Masanori; Ishioka, Katsura; Hagiwara, Masayuki; Miyazaki, Yasumasa; Shinojima, Toshiaki; Miyajima, Akira; Oya, Mototsugu.

In: Urology, Vol. 85, No. 5, 19056, 01.05.2015, p. 1151-1155.

Research output: Contribution to journalArticle

Maeda, T, Kikuchi, E, Hasegawa, M, Ishioka, K, Hagiwara, M, Miyazaki, Y, Shinojima, T, Miyajima, A & Oya, M 2015, 'Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia', Urology, vol. 85, no. 5, 19056, pp. 1151-1155. https://doi.org/10.1016/j.urology.2015.01.028
Maeda, Takahiro ; Kikuchi, Eiji ; Hasegawa, Masanori ; Ishioka, Katsura ; Hagiwara, Masayuki ; Miyazaki, Yasumasa ; Shinojima, Toshiaki ; Miyajima, Akira ; Oya, Mototsugu. / Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia. In: Urology. 2015 ; Vol. 85, No. 5. pp. 1151-1155.
@article{161c37d3821c45ea8d55a96ffa8521d2,
title = "Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia",
abstract = "Objective To evaluate the clinical response and adverse events (AEs) of solifenacin (SOL) or mirabegron (MIR) in benign prostatic hyperplasia patients with persistent overactive bladder (OAB) symptoms after dutasteride (DUT) treatment. Methods Fifty cases with residual OAB symptom score (OABSS) ≥5 and OABSS Q3 ≥2 after at least 6 months treatment of DUT were included in this study. Patients were administered 5 mg/d of SOL (N = 25) or 50 mg/d of MIR (N = 25), and International Prostate Symptom Score (IPSS) and OABSS were prospectively collected at 4 and 12 weeks. The safety was evaluated by changes in postvoided residual urine volume and the incidence of AEs. Results After DUT administration, the mean prostate volume, IPSS, and OABSS were 39.0 mL, 17.6, and 8.1, respectively. SOL 5 mg significantly reduced the IPSS, OABSS, and OABSS Q3 at 4 and at 12 weeks (-3.1, -2.7, -1.3; P <.05); however, 4 patients could not continue the SOL treatment owing to AEs. All patients could continue the 12 weeks of MIR treatment, and MIR 50 mg reduced IPSS and OABSS at 4 weeks and reduced IPSS, OABSS, and the OABSS Q3 (-3.0, -2.5, -0.9; P <.05) at 12 weeks. Postvoided residual urine volume increased by ≥100 mL after treatment in 2 cases in the SOL group but not in any patient in the MIR group. Conclusion Additional SOL or MIR might result in amelioration of the persistent OAB symptom after DUT treatment in patients with an enlarged prostate.",
author = "Takahiro Maeda and Eiji Kikuchi and Masanori Hasegawa and Katsura Ishioka and Masayuki Hagiwara and Yasumasa Miyazaki and Toshiaki Shinojima and Akira Miyajima and Mototsugu Oya",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.urology.2015.01.028",
language = "English",
volume = "85",
pages = "1151--1155",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Solifenacin or Mirabegron Could Improve Persistent Overactive Bladder Symptoms After Dutasteride Treatment in Patients With Benign Prostatic Hyperplasia

AU - Maeda, Takahiro

AU - Kikuchi, Eiji

AU - Hasegawa, Masanori

AU - Ishioka, Katsura

AU - Hagiwara, Masayuki

AU - Miyazaki, Yasumasa

AU - Shinojima, Toshiaki

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Objective To evaluate the clinical response and adverse events (AEs) of solifenacin (SOL) or mirabegron (MIR) in benign prostatic hyperplasia patients with persistent overactive bladder (OAB) symptoms after dutasteride (DUT) treatment. Methods Fifty cases with residual OAB symptom score (OABSS) ≥5 and OABSS Q3 ≥2 after at least 6 months treatment of DUT were included in this study. Patients were administered 5 mg/d of SOL (N = 25) or 50 mg/d of MIR (N = 25), and International Prostate Symptom Score (IPSS) and OABSS were prospectively collected at 4 and 12 weeks. The safety was evaluated by changes in postvoided residual urine volume and the incidence of AEs. Results After DUT administration, the mean prostate volume, IPSS, and OABSS were 39.0 mL, 17.6, and 8.1, respectively. SOL 5 mg significantly reduced the IPSS, OABSS, and OABSS Q3 at 4 and at 12 weeks (-3.1, -2.7, -1.3; P <.05); however, 4 patients could not continue the SOL treatment owing to AEs. All patients could continue the 12 weeks of MIR treatment, and MIR 50 mg reduced IPSS and OABSS at 4 weeks and reduced IPSS, OABSS, and the OABSS Q3 (-3.0, -2.5, -0.9; P <.05) at 12 weeks. Postvoided residual urine volume increased by ≥100 mL after treatment in 2 cases in the SOL group but not in any patient in the MIR group. Conclusion Additional SOL or MIR might result in amelioration of the persistent OAB symptom after DUT treatment in patients with an enlarged prostate.

AB - Objective To evaluate the clinical response and adverse events (AEs) of solifenacin (SOL) or mirabegron (MIR) in benign prostatic hyperplasia patients with persistent overactive bladder (OAB) symptoms after dutasteride (DUT) treatment. Methods Fifty cases with residual OAB symptom score (OABSS) ≥5 and OABSS Q3 ≥2 after at least 6 months treatment of DUT were included in this study. Patients were administered 5 mg/d of SOL (N = 25) or 50 mg/d of MIR (N = 25), and International Prostate Symptom Score (IPSS) and OABSS were prospectively collected at 4 and 12 weeks. The safety was evaluated by changes in postvoided residual urine volume and the incidence of AEs. Results After DUT administration, the mean prostate volume, IPSS, and OABSS were 39.0 mL, 17.6, and 8.1, respectively. SOL 5 mg significantly reduced the IPSS, OABSS, and OABSS Q3 at 4 and at 12 weeks (-3.1, -2.7, -1.3; P <.05); however, 4 patients could not continue the SOL treatment owing to AEs. All patients could continue the 12 weeks of MIR treatment, and MIR 50 mg reduced IPSS and OABSS at 4 weeks and reduced IPSS, OABSS, and the OABSS Q3 (-3.0, -2.5, -0.9; P <.05) at 12 weeks. Postvoided residual urine volume increased by ≥100 mL after treatment in 2 cases in the SOL group but not in any patient in the MIR group. Conclusion Additional SOL or MIR might result in amelioration of the persistent OAB symptom after DUT treatment in patients with an enlarged prostate.

UR - http://www.scopus.com/inward/record.url?scp=84933513517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933513517&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2015.01.028

DO - 10.1016/j.urology.2015.01.028

M3 - Article

C2 - 25770728

AN - SCOPUS:84933513517

VL - 85

SP - 1151

EP - 1155

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

M1 - 19056

ER -